ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
임질 치료제 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 18억 8,000만 달러에서 2025년에는 19억 7,000만 달러에 달하고, CAGR 5.1%를 나타낼 전망입니다. 실적기간의 성장은 임균의 내성화, 임질의 유병률의 상승, 항균제 내성(AMR)의 유병률의 상승, 항생제 내성 증가, 이중 치료법의 사용 증가에 기인하고 있습니다.
임질 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.0%를 나타내 24억 달러로 성장할 전망입니다. 예측기간의 성장은 성감염증 증가, 맞춤형 의료에 대한 주목 증가, 항생제 내성 패턴의 상승, 임질 이환율 증가, 효과적인 치료에 대한 수요 증가에 기인하는 것으로 예측됩니다. 예측기간의 주요 동향으로는 기술 개발, 고도진단검사, 신규치료제의 개발, 병용요법의 개발, 신속한 의약품 승인에 대한 규제당국의 지원 등을 들 수 있습니다.
임질 치료제는 임균에 의해 유발된 성감염증(STI)인 임질의 관리 및 치유에 사용되는 치료법 및 약물을 말합니다. 이러한 치료에는 주로 항생제가 사용되며, 내성균의 발생을 방지하고 효과적인 제균을 보장하기 위해 병용 투여되는 경우가 많습니다.
임질 치료제의 주요 분류에는 항생제, 병용 요법 및 단독 요법이 있습니다. 항생제는 특히 임질의 원인 박테리아를 멸균하도록 설계되었으며 일반적으로 아지트로 마이신과 세프 트리 악손과 같은 약물을 포함합니다. 이러한 치료는 경구, 정맥 내, 근육내 경로로 투여되며 소아, 성인, 노인 등 다양한 연령대에 맞게 조정됩니다. 유통 채널에는 병원 약국, 소매 약국, 온라인 약국이 포함되며, 주요 최종 사용자는 병원, 클리닉, 재택 간호 현장입니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 설문조사 보고서는 임질 치료제 산업 세계 시장 규모, 지역 점유율, 임질 치료제 시장 점유율을 가진 경쟁업체, 상세한 임질 치료제 시장 부문, 시장 동향, 비즈니스 기회 등 임질 치료제 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 임질 치료제 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 5.0%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 상승은 스페인이나 중국에서 조달하는 세팔로스포린계 항생제와 항균제 검사 키트의 비용을 밀어 올리고, 항생제 내성의 과제를 악화시키고, 성 감염증 클리닉 검사(STD) 비용을 증가시킴으로써 미국의 공중 보건 시스템에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
성감염증(STI)의 이환율 증가는 앞으로 수년간 임질 치료제 시장 성장을 이끌 것으로 예측됩니다. STI는 성적 접촉에 의해 감염되는 감염으로 박테리아, 바이러스 및 기생충에 의해 유발됩니다. STI 증가는 무방비적인 성행위, 인식과 교육의 부족, 성적 파트너 증가, 콘돔 사용의 감소, 검사나 치료의 불충분함과 지연 등의 요인에 기인하고 있습니다. 임질 치료제는 임균을 표적으로 하고 합병증을 예방하고 감염을 줄임으로써 STI 치료에 중요한 역할을 합니다. 예를 들어 2024년 6월 네덜란드 정부 기관인 국립공중보건·환경연구소는 SHC로 진단받은 임질환자가 크게 증가하여 2022년 1만 600건에서 2023년 1만 3,853건으로 증가했다고 보고했습니다. 이러한 STI의 유병률 증가는 임질 치료제 시장 확대에 박차를 가하고 있습니다.
임질 치료제 시장 주요 기업은 신속한 중합효소 연쇄반응(PCR) 검사와 같은 혁신적인 솔루션의 개발에 주력하고 있으며, 의료 현장에서 신속하고 정확하게 병원체를 검출하고 항생제 내성을 분석할 수 있도록 하고 있습니다. 신속 PCR 검사는 특정 DNA 또는 RNA 서열을 증폭 및 검출하는 진단 도구로 병원체와 유전 물질의 신속한 동정을 가능하게 합니다. 예를 들어, 2024년 2월 미국의 의료 기술 기업인 Visby Medical, Inc.는 항균제 내성 검사를 포함한 임질 검사를 발표했습니다. 이 신속한 진단 검사는 임질의 원인균인 임균의 존재를 확인하는 동시에 일부 임균이 내성을 획득하는 항생제인 시프로플록사신에 대한 감수성을 평가합니다. 이 검사는 휴대용 기구가 필요 없는 PCR 플랫폼의 일부로, POC(Point-of-Care)에서 즉시 검사를 가능하게 합니다. 미국의 비영리 단체인 CARB-X로부터의 자금을 제공하여 개발된 이 검사는 남성의 클라미디아 트라코마티스와 트리코모나스 질염 등 다른 성 감염증의 검출에도 확대할 예정입니다.
2024년 11월 미국의 바이오 제약회사인 Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator(CARB-X)는 항균제 내성(AMR) 대응을 강화하고 임질 치료의 과제를 해결하기 위해 클린턴 헬스 액세스 이니셔티브(CHAI)와 제휴했습니다. 본 제휴는 저·중소득국에서 임질의 진단, 예방, 치료에 관한 임상 요구를 평가하고 시장 장벽을 극복하는 것을 목적으로 하고 있으며, 특히 약물 내성 임균에 초점을 맞추어 환자 케어의 향상과 효과적인 AMR 솔루션에 대한 접근을 확대하는 것을 목적으로 하고 있습니다. 미국에 본사를 둔 보건 단체 CHAI는 진단, 치료, 예방 전략 등 임질 치료제에 대한 접근성을 개선하기 위해 노력하고 있습니다.
임질 치료제 시장은 진단 검사 서비스, 성 건강 상담 서비스, 원격 의료, 온라인 상담 등의 서비스를 제공하는 기업이 얻는 수익으로 구성되어 있습니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. 임질 치료제 시장에는 소아용 제제, 단일 용량 요법, 설폰아미드 및 페니실린 판매도 포함됩니다. 이 시장의 가치는 "Factory Gate"가치, 즉 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함)이든 직접 최종 고객이든, 상품 제조자 또는 제조자가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 임질 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 임질 치료제 시장 : 성장률 분석
세계의 임질 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 임질 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 임질 치료제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 임질 치료제 시장 : 치료 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항생제
병용 요법
단일 요법
세계의 임질 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
정맥주사
근육주사
세계의 임질 치료제 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아
성인
노인
세계의 임질 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 임질 치료제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
홈케어
세계의 임질 치료제 시장 : 항생제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
베타-락탐계
마크로라이드계
플루오로퀴놀론계
아미노글리코시드
세계의 임질 치료제 시장 : 병용 요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
이중 항생제 요법
삼중 항생제 요법
세계의 임질 치료제 시장 : 단일 요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일 항생제 치료
기타 단일요법 옵션
제7장 지역별/국가별 분석
세계의 임질 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 임질 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
임질 치료제 시장 : 경쟁 구도
임질 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Becton Dickinson and Company
Hologic Inc.
Aurobindo Pharma Limited
Innoviva Inc.
Debiopharm Group
Achilles Vaccines Srl
Melinta Therapeutics LLC
VenatoRx Pharmaceuticals Inc.
Evofem Biosciences Inc.
Recce Pharmaceuticals Ltd.
Therapyx Inc.
Entasis Therapeutics Inc.
Apotex Inc.
Alopexx Pharmaceuticals LLC
Summit Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
임질 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
임질 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
임질 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Gonorrhea therapeutics refer to treatments and medications used to manage and cure gonorrhea, a sexually transmitted infection (STI) caused by *Neisseria gonorrhoeae. These treatments primarily rely on antibiotics, often administered in combination to prevent resistance and ensure effective bacterial eradication.
The main classes of gonorrhea therapeutics include antibiotics, combination therapy, and monotherapy. Antibiotics are specifically designed to eliminate the bacteria responsible for gonorrhea, commonly including drugs such as azithromycin and ceftriaxone. These treatments are administered through oral, intravenous, and intramuscular routes and are tailored for different age groups, including pediatric, adult, and geriatric patients. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, while the primary end users comprise hospitals, clinics, and home care settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The gonorrhea therapeutics market research report is one of a series of new reports from The Business Research Company that provides gonorrhea therapeutics market statistics, including the gonorrhea therapeutics industry global market size, regional shares, competitors with the gonorrhea therapeutics market share, detailed gonorrhea therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gonorrhea therapeutics industry. This gonorrhea therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gonorrhea therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to the growing resistance of Neisseria gonorrhoeae, rising prevalence of gonorrhea, increasing prevalence of antimicrobial resistance (AMR), increasing antibiotic resistance, and increasing use of dual therapy treatments.
The gonorrhea therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.4 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing sexually transmitted infections, a growing focus on personalized medicine, rising antibiotic resistance patterns, a growing incidence of gonorrhea, and growing demand for effective treatment. Major trends in the forecast period include technological developments, advanced diagnostic tests, the development of new therapeutics, the development of combination therapies, and regulatory support for expedited drug approvals.
The forecast of 5.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. public health systems by driving up the cost of cephalosporin antibiotics and antimicrobial test kits sourced from Spain and China, exacerbating antibiotic resistance challenges and increasing Sexually Transmitted Disease clinic testing(STD) clinic testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the gonorrhea therapeutics market in the coming years. STIs are infections transmitted through sexual contact and are caused by bacteria, viruses, or parasites. The increase in STIs is attributed to factors such as unprotected sex, lack of awareness or education, a higher number of sexual partners, reduced condom use, and inadequate or delayed testing and treatment. Gonorrhea therapeutics play a crucial role in treating STIs by targeting the Neisseria gonorrhoeae bacteria, preventing complications, and reducing transmission. For example, in June 2024, the National Institute for Public Health and the Environment, a Netherlands-based government agency, reported a significant rise in gonorrhea cases diagnosed at SHCs, increasing from 10,600 in 2022 to 13,853 in 2023, reflecting a 31% year-over-year growth. This growing prevalence of STIs is fueling the expansion of the gonorrhea therapeutics market.
Leading companies in the gonorrhea therapeutics market are focused on developing innovative solutions, such as rapid polymerase chain reaction (PCR) tests, to enable quick and accurate pathogen detection and antibiotic resistance analysis at the point of care. A rapid PCR test is a diagnostic tool that amplifies and detects specific DNA or RNA sequences, allowing for fast identification of pathogens or genetic material. For instance, in February 2024, Visby Medical, Inc., a US-based medical technology company, introduced a gonorrhea test that includes an antimicrobial resistance check. This rapid diagnostic test identifies the presence of Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, while also assessing its susceptibility to ciprofloxacin, an antibiotic to which some gonorrhea strains have developed resistance. The test is part of a portable, instrument-free PCR platform that allows immediate testing at the point of care. Developed with funding from the US non-profit organization CARB-X, the company plans to expand the test to detect other sexually transmitted infections, including Chlamydia trachomatis and Trichomonas vaginalis, in men.
In November 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a US-based biopharmaceutical company, partnered with the Clinton Health Access Initiative (CHAI) to enhance antimicrobial resistance (AMR) response and address gonorrhea treatment challenges. This collaboration aims to assess clinical needs and overcome market barriers for gonorrhea diagnostics, prevention, and treatment in low- and middle-income countries, with a focus on drug-resistant Neisseria gonorrhoeae to improve patient care and expand access to effective AMR solutions. CHAI, a US-based health organization, works to improve access to gonorrhea therapeutics, including diagnostics, treatments, and preventive strategies.
Major players in the gonorrhea therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Becton Dickinson and Company, Hologic Inc., Aurobindo Pharma Limited, Innoviva Inc., Debiopharm Group, Achilles Vaccines S.r.l., Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Evofem Biosciences Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Alopexx Pharmaceuticals LLC, and Summit Therapeutics Inc.
North America was the largest region in the gonorrhea therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonorrhea therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gonorrhea therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gonorrhea therapeutics market consists of revenues earned by entities by providing services such as diagnostic testing services, sexual health and counseling services, telemedicine, and online consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The gonorrhea therapeutics market also includes sales of pediatric formulations, single-dose regimens, sulfonamides, and penicillin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gonorrhea Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gonorrhea therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gonorrhea therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gonorrhea therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapeutic Class: Antibiotics; Combination Therapy; Monotherapy
2) By Route Of Administration: Oral; Intravenous; Intramuscular
3) By Age Group: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Clinics; Home Care
Subsegments:
1) By Antibiotics: Beta-lactams; Macrolides; Fluoroquinolones; Aminoglycosides
2) By Combination Therapy: Dual Antibiotic Therapy; Triple Antibiotic Therapy
3) By Monotherapy: Single Antibiotic Treatment; Other Monotherapy Options
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gonorrhea Therapeutics Market Characteristics
3. Gonorrhea Therapeutics Market Trends And Strategies
4. Gonorrhea Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Gonorrhea Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Gonorrhea Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gonorrhea Therapeutics Market Growth Rate Analysis
5.4. Global Gonorrhea Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gonorrhea Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gonorrhea Therapeutics Total Addressable Market (TAM)
6. Gonorrhea Therapeutics Market Segmentation
6.1. Global Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotics
Combination Therapy
Monotherapy
6.2. Global Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Intramuscular
6.3. Global Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.4. Global Gonorrhea Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Gonorrhea Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Care
6.6. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Beta-lactams
Macrolides
Fluoroquinolones
Aminoglycosides
6.7. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dual Antibiotic Therapy
Triple Antibiotic Therapy
6.8. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Antibiotic Treatment
Other Monotherapy Options
7. Gonorrhea Therapeutics Market Regional And Country Analysis
7.1. Global Gonorrhea Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gonorrhea Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gonorrhea Therapeutics Market
9.1. China Gonorrhea Therapeutics Market Overview
9.2. China Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gonorrhea Therapeutics Market
10.1. India Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gonorrhea Therapeutics Market
11.1. Japan Gonorrhea Therapeutics Market Overview
11.2. Japan Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gonorrhea Therapeutics Market
12.1. Australia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gonorrhea Therapeutics Market
13.1. Indonesia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gonorrhea Therapeutics Market
14.1. South Korea Gonorrhea Therapeutics Market Overview
14.2. South Korea Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gonorrhea Therapeutics Market
15.1. Western Europe Gonorrhea Therapeutics Market Overview
15.2. Western Europe Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gonorrhea Therapeutics Market
16.1. UK Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gonorrhea Therapeutics Market
17.1. Germany Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gonorrhea Therapeutics Market
18.1. France Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gonorrhea Therapeutics Market
19.1. Italy Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gonorrhea Therapeutics Market
20.1. Spain Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gonorrhea Therapeutics Market
21.1. Eastern Europe Gonorrhea Therapeutics Market Overview
21.2. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gonorrhea Therapeutics Market
22.1. Russia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gonorrhea Therapeutics Market
23.1. North America Gonorrhea Therapeutics Market Overview
23.2. North America Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gonorrhea Therapeutics Market
24.1. USA Gonorrhea Therapeutics Market Overview
24.2. USA Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gonorrhea Therapeutics Market
26.1. South America Gonorrhea Therapeutics Market Overview
26.2. South America Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gonorrhea Therapeutics Market
27.1. Brazil Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gonorrhea Therapeutics Market
28.1. Middle East Gonorrhea Therapeutics Market Overview
28.2. Middle East Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gonorrhea Therapeutics Market
29.1. Africa Gonorrhea Therapeutics Market Overview
29.2. Africa Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gonorrhea Therapeutics Market Competitive Landscape And Company Profiles
